Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 7/20 | 0.76 |
| ▸ | PTPN1 | P18031 | 12/20 | 0.69 |
| ▸ | ACP1 | P24666 | 12/20 | 0.69 |
| ▸ | PTPN2 | P17706 | 6/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17302235 | 0.93 | CA9 (0.86) | CA9PTPN1ACP1PTPN2 | |
| SCHEMBL17295391 | 0.82 | CA9 (0.84) | CA9PTPN1ACP1PTPN2 | |
| SCHEMBL17295393 | 0.82 | CA9 (0.84) | CA9PTPN1ACP1PTPN2 | |
| SCHEMBL17302232 | 0.82 | CA9 (0.69) | CA9PTPN1ACP1PTPN2 | |
| SCHEMBL17302233 | 0.81 | CA9 (0.68) | CA9PTPN1ACP1PTPN2 | |
| SCHEMBL17295317 | 0.78 | PTPN1 (0.72) | CA9PTPN1ACP1PTPN2 | |
| SCHEMBL17295318 | 0.78 | PTPN1 (0.72) | CA9PTPN1ACP1PTPN2 | |
| SCHEMBL17309309 | 0.77 | CA9 (0.76) | CA9PTPN1ACP1PTPN2 | |
| SCHEMBL30173481 | 0.77 | PPARG (0.73) | — | |
| SCHEMBL19481512 | 0.77 | CA9 (0.76) | CA9PTPN1ACP1PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190119265-A1 | THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | UNIVERSITAT BERN (CH) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119265-A1 | THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | GRIN2B, IL1B, GRIA4 | CA9 4745/4885PTPN1 2202/4885ACP1 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.